"Established in 2009. Hawaii Pacific Neuroscience (HPN) started in 2009 with the sole purpose of meeting unmet needs in our community and doing so with excellence! Since then, our company has grown to be one of the largest and leading providers of Neuroscience care in Hawaii, serving over 30,000 patient visits and over 700 research visits in 2019 alone. We now have 4 locations in Kailua, Honolulu, Waipahu, and Kailua-Kona."

During the past decade, Hawaii Pacific Neuroscience conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 8 clinical trials were completed, i.e. on average, 27.6% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 8 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hawaii Pacific Neuroscience" #1 sponsor was "Biogen" with 3 trials, followed by "SK Life Science, Inc." with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Jazz Pharmaceuticals" with 2 trials sponsored and "Longboard Pharmaceuticals" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hawaii Pacific Neuroscience" #1 collaborator was "Acorda Therapeutics" with 1 trials as a collaborator, "Alzheimer's Association" with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "Clinilabs, Inc." with 1 trials as a collaborator and "Covance" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Hawaii Pacific Neuroscience" are "Epilepsy" (3 trials), "Parkinson Disease" (3 trials), "Alzheimer Disease" (2 trials), "Alzheimer's Disease" (2 trials) and "Developmental and Epileptic Encephalopathy" (2 trials). Many other conditions were trialed in "Hawaii Pacific Neuroscience" in a lesser frequency.

Most popular intervention types in "Hawaii Pacific Neuroscience" are "Drug" (29 trials), "Other" (2 trials), "Biological" (1 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Cenobamate" (2 trials), "LP352" (2 trials), "Lasmiditan" (2 trials) and "Placebos" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hawaii Pacific Neuroscience" are 30 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hawaii Pacific Neuroscience". undefined are not yet recruiting, 11 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 11 completed trials in Hawaii Pacific Neuroscience, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Hawaii Pacific Neuroscience, 3 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".

Hawaii Pacific Neuroscience has several departments that took part in Clinical trials: "Hawaii Pacific Neuroscience Clinical Research Center" - 2 trials